Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]
In development [GID-TA10691] Expected publication date: 13 July 2022
Search results
483 results
-
-
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping [ID1387]
In development [GID-TA10846] Expected publication date: TBC
-
Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]
In development [GID-TA10581] Expected publication date: TBC
-
Dapagliflozin for treating heart failure with preserved ejection fraction ID1648
In development [GID-TA10942] Expected publication date: TBC
-
Ranibizumab port delivery system for treating wet age-related macular degeneration [ID3983]
In development [GID-TA10879] Expected publication date: TBC
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]
In development [GID-TA10792] Expected publication date: 14 September 2022
-
Obesity - phentermine (with topiramate) [ID543]
In development [GID-TAG439] Expected publication date: TBC
-
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
In development [GID-TA10322] Expected publication date: TBC
-
Tofacitinib for treating active ankylosing spondylitis [ID3865]
In development [GID-TA10771] Expected publication date: 17 August 2022
-
Upadacitinib for treating active ankylosing spondylitis [ID3848]
In development [GID-TA10735] Expected publication date: 17 August 2022
-
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development [GID-TA10489] Expected publication date: TBC
-
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: 25 January 2023
-
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
In development [GID-TAG424] Expected publication date: TBC
-
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
In development [GID-TAG433] Expected publication date: TBC
-
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
In development [GID-TA10363] Expected publication date: TBC
-
Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]
In development [GID-TA10271] Expected publication date: TBC
-
Hypercholesterolemia - mipomersen [ID524]
In development [GID-TAG437] Expected publication date: TBC
-
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
-
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]
In development [GID-TAG369] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]
In development [GID-TA10751] Expected publication date: 13 July 2022
-
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]
In development [GID-TAG337] Expected publication date: TBC
-
Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]
In development [GID-TA10566] Expected publication date: TBC
-
Lung cancer (non-small-cell) - cetuximab [ID9]
In development [GID-TAG395] Expected publication date: TBC
-
Generalised anxiety disorder - quetiapine [ID347]
In development [GID-TAG421] Expected publication date: TBC
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
In development [GID-TA10311] Expected publication date: TBC
-
Mobocertinib for treating EGFR Exon 20 insertion-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3984]
In development [GID-TA10881] Expected publication date: 12 October 2022
-
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
In development [GID-TA10637] Expected publication date: TBC
-
Faricimab for treating diabetic macular oedema [ID3899]
In development [GID-TA10798] Expected publication date: TBC
-
Risankizumab for previously treated active psoriatic arthritis [ID1399]
In development [GID-TA10819] Expected publication date: 19 October 2022
-
Faricimab for treating wet age-related macular degeneration [ID3898 ]
In development [GID-TA10799] Expected publication date: TBC
-
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]
In development [GID-TA10781] Expected publication date: TBC
-
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]
In development [GID-TA10552] Expected publication date: 13 July 2022
-
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis [ID1581]
In development [GID-TA10740] Expected publication date: 13 July 2022
-
Onasemnogene abeparvovec for treating spinal muscular atrophy (review of HST15) [ID4051]
In development [GID-HST10053] Expected publication date: TBC
-
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
In development [GID-TA10822] Expected publication date: TBC
-
Venetoclax for treating chronic lymphocytic leukaemia (CDF review of TA487) [ID3886]
In development [GID-TA10890] Expected publication date: 15 June 2022
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 17 August 2022
-
Ibrutinib for treating Waldenstrom's macroglobulinaemia (CDF Review of TA491) [ID3778]
In development [GID-TA10827] Expected publication date: 08 June 2022
-
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]
In development [GID-HST10034] Expected publication date: 20 July 2022
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: 20 July 2022
-
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]
In development [GID-TA10749] Expected publication date: TBC
-
Sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast cancer after 2 or more therapies [ID3942]
In development [GID-TA10829] Expected publication date: 17 August 2022
-
Olaparib for adjuvant treatment of high-risk HER2-negative, BRCA-positive early breast cancer after chemotherapy [ID3893]
In development [GID-TA10903] Expected publication date: 03 January 2023
-
Pegunigalsidase alfa for treating Fabry disease [ID3904]
In development [GID-TA10790] Expected publication date: TBC
-
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]
In development [GID-TA10391] Expected publication date: TBC
-
Somatrogon for treating growth disturbance in children and young people aged 3 and over [ID5086]
In development [GID-TA10989] Expected publication date: TBC
-
Clopidogrel genotype testing after ischaemic stroke (provisional title)
In development [GID-DG10054] Expected publication date: 16 August 2023
-
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
In development [GID-TA11036] Expected publication date: TBC
-
Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]
In development [GID-TA10866] Expected publication date: 04 January 2023